Overexpression and Oncogenic Role of RIPK3 in Acute Myeloid Leukemia Associated with Specific Subtypes and Treatment Outcome

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Feb 13

PMID 39948488

Authors

Yun Wang

Ting-Juan Zhang

Liu-Chao Zhang

Zi-Jun Xu

Ming-Qiang Chu

Yang-Jing Zhao

Jiang Lin

Jun Qian

Jing-Dong Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Receptor-interacting protein kinase 3 (RIPK3) has been implicated in the pathogenesis of diverse human cancers. However, the role of RIPK3 in acute myeloid leukemia (AML) is not fully understood, which needs further research and clarification.

Methods: We first identified the expression and clinical prognostic value of RIPK3 in AML through a public database and further validated in our research cohort. In addition, the biological function of RIPK3 in leukemic development was further verified through in vitro experiments.

Results: Based on the GEPIA database, we screened that RIPK3 overexpression among RIPK family was associated with poor prognosis in AML. Afterwards, another independent cohort from our research center further confirmed the expression pattern of RIPK3 in AML patients. Clinically, increased RIPK3 expression was closely related to specific subtypes of AML, such as FAB-M4/M5, normal karyotype and NPM1 mutation. The significant association of RIPK3 overexpression with FAB-M4/M5 was further validated in AML cell lines. Notably, AML patients with RIPK3 overexpression received transplantation presented a markedly longer survival than those just receiving chemotherapy, whereas those with RIPK3 underexpression showed similar survival between transplantation and chemotherapy group. Bioinformatics analysis showed the significant association of RIPK3 expression with diverse oncogenes/tumor suppressor genes and tumor-related biological processes in AML. Subsequently, we further performed functional experiments in vitro confirmed the potential oncogenic role of RIPK3 in AML.

Conclusions: Overexpression of RIPK3 was associated with specific subtypes of AML, such as FAB-M4/M5, normal karyotype and NPM1 mutation, and may facilitate the leukemic development. Moreover, RIPK3 overexpression was associated poor prognosis, and may guide treatment choice in AML.

References

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

Lalaoui N, Hanggi K, Brumatti G, Chau D, Nguyen N, Vasilikos L . Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. Cancer Cell. 2016; 29(2):145-58. DOI: 10.1016/j.ccell.2016.01.006. View

Kobayashi N, Oda T, Takizawa M, Ishizaki T, Tsukamoto N, Yokohama A . Integrin α7 and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma. Cancers (Basel). 2020; 12(2). PMC: 7072541. DOI: 10.3390/cancers12020363. View

Tan Y, Sementino E, Cheung M, Peri S, Menges C, Kukuyan A . Somatic Epigenetic Silencing of Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. Clin Cancer Res. 2020; 27(4):1200-1213. PMC: 7887036. DOI: 10.1158/1078-0432.CCR-18-3683. View

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

DiNardo C, Erba H, Freeman S, Wei A . Acute myeloid leukaemia. Lancet. 2023; 401(10393):2073-2086. DOI: 10.1016/S0140-6736(23)00108-3. View

Liu S, Joshi K, Denning M, Zhang J . RIPK3 signaling and its role in the pathogenesis of cancers. Cell Mol Life Sci. 2021; 78(23):7199-7217. PMC: 9044760. DOI: 10.1007/s00018-021-03947-y. View

Hockendorf U, Yabal M, Herold T, Munkhbaatar E, Rott S, Jilg S . RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell. 2016; 30(1):75-91. DOI: 10.1016/j.ccell.2016.06.002. View

Yang C, Li J, Yu L, Zhang Z, Xu F, Jiang L . Regulation of RIP3 by the transcription factor Sp1 and the epigenetic regulator UHRF1 modulates cancer cell necroptosis. Cell Death Dis. 2017; 8(10):e3084. PMC: 5682651. DOI: 10.1038/cddis.2017.483. View

10.

Zhang T, Xu Z, Wen X, Gu Y, Ma J, Yuan Q . SLIT2 promoter hypermethylation-mediated SLIT2-IT1/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm. Leukemia. 2022; 36(10):2488-2498. DOI: 10.1038/s41375-022-01659-1. View

11.

Koo G, Morgan M, Lee D, Kim W, Yoon J, Koo J . Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015; 25(6):707-25. PMC: 4456623. DOI: 10.1038/cr.2015.56. View

12.

Xin J, You D, Breslin P, Li J, Wei W, Cannova J . Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway. Leukemia. 2016; 31(5):1154-1165. PMC: 5457287. DOI: 10.1038/leu.2016.287. View

13.

Gu Y, Chu M, Xu Z, Yuan Q, Zhang T, Lin J . Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation. BMC Med Genomics. 2022; 15(1):38. PMC: 8886923. DOI: 10.1186/s12920-022-01193-0. View

14.

Fukasawa M, Kimura M, Morita S, Matsubara K, Yamanaka S, Endo C . Microarray analysis of promoter methylation in lung cancers. J Hum Genet. 2006; 51(4):368-374. DOI: 10.1007/s10038-005-0355-4. View

15.

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

16.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

17.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

18.

Bryant A, Palma C, Jayaswal V, Yang Y, Lutherborrow M, Ma D . miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death. Mol Cancer. 2012; 11:8. PMC: 3306826. DOI: 10.1186/1476-4598-11-8. View

19.

Zhou J, Zhao Y, Leng J, Gu Y, Xu Z, Ma J . DNA methylation-mediated differential expression of DLX4 isoforms has opposing roles in leukemogenesis. Cell Mol Biol Lett. 2022; 27(1):59. PMC: 9327205. DOI: 10.1186/s11658-022-00358-0. View

20.

Hwang S . Classification of acute myeloid leukemia. Blood Res. 2020; 55(S1):S1-S4. PMC: 7386892. DOI: 10.5045/br.2020.S001. View